Australia Cannot Settle Its Device Price Fight While the Service Sits Inside the Price
Both sides are fighting over a number nobody can produce. The evaluation went underneath them and named the reason: the service is inside the price.
Both sides are fighting over a number nobody can produce. The evaluation went underneath them and named the reason: the service is inside the price.
Committing 30% of a health ministry’s requirement at agreed prices means deciding not to buy the cheapest product. Somebody is paying for that.
Freenome defined its population by the failure of the existing pathway, not by anything measurable in the patient. That is the decision worth reading.
BD is not testing a product against a competitor. It is testing whether an indication can be brought into existence, with no label, code or precedent.
Two patients with severe aphasia solved formal logic problems as well as controls. The language network stayed quiet through both reasoning types.
Nobody gained insurance access. Designation is the gate before the negotiation. The real story is that both lead technologies remove a specialist.
Everything FastWave sells is comparative. The word its chief executive used is clearance, and clearance means substantially equivalent.
Two MHRA authorisations in two days. One drug is too common to fund, the other too rare to prioritise. Neither is on the NHS.
CMS Opened a Same-Day Coverage Lane for Devices and Closed the Payment Route Underneath It
Washington Narrowed the Childhood Schedule, and the Insurer Backstop Quietly Stopped Being One